1. CDC. Diagnoses of HIV infection in the United States and dependent areas, 2019. May 2021. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 1 Nov 2022.
2. CDC. Ending the HIV epidemic. April 1, 2021. https://www.cdc.gov/endhiv/index.html. Accessed 1 Nov 2022.
3. DESCOVY PI. DESCOVY® (emtricitabine and tenofovir alafenamide) tablets, for oral use. Gilead Sciences; January 2022. https://www.gilead.com/~/media/files/pdfs/medicines/hiv/descovy/descovy_pi.pdf?la=en. Accessed 1 Nov 2022.
4. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
5. Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6): e1003670.